See more : Shenzhen Sunnypol Optoelectronics Co.,Ltd. (002876.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Mind Medicine (MindMed) Inc. (MNMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mind Medicine (MindMed) Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Altimeter Growth Corp. 2 (AGCB) Income Statement Analysis – Financial Results
- L’Oréal S.A. (LRLCY) Income Statement Analysis – Financial Results
- Sau San Tong Holdings Limited (8200.HK) Income Statement Analysis – Financial Results
- Kin and Carta plc (SVPLF) Income Statement Analysis – Financial Results
- Sungshin Cement Co., Ltd (004985.KS) Income Statement Analysis – Financial Results
Mind Medicine (MindMed) Inc. (MNMD)
About Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.16M | 3.22M | 2.62M | 0.00 | 6.68K | 6.68K | 5.50K | 0.00 | 0.00 |
| Gross Profit | -3.16M | -3.22M | -2.62M | 0.00 | -6.68K | -6.68K | -5.50K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 48.96M | 36.17M | 34.79M | 18.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 41.74M | 30.16M | 59.07M | 14.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 41.74M | 30.16M | 59.07M | 14.40M | 461.50K | 855.26K | 1.23M | 111.25K | 94.55K |
| Other Expenses | 0.00 | 2.00K | 106.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 93.87M | 66.33M | 93.85M | 33.03M | 461.50K | 855.26K | 1.23M | 111.25K | 94.55K |
| Cost & Expenses | 93.87M | 66.33M | 93.85M | 33.03M | 468.18K | 861.94K | 1.24M | 111.25K | 94.55K |
| Interest Income | 4.66M | 1.50M | 0.00 | 0.00 | 0.00 | 4.00K | 8.40K | 1.20K | 1.90K |
| Interest Expense | 0.00 | 1.50M | 359.00K | 164.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.16M | 3.22M | 2.62M | 206.30K | 6.68K | 6.68K | 5.50K | 0.00 | 0.39 |
| EBITDA | -92.57M | -53.57M | -91.22M | -33.77M | -1.11M | -851.26K | -1.51M | -111.25K | -92.66K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -93.87M | -66.33M | -96.36M | -33.03M | -468.18K | -861.94K | -1.24M | -111.25K | -94.55K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.87M | 9.54M | -339.00K | -907.00K | -647.63K | 4.00K | 8.40K | -68.65K | 1.89K |
| Income Before Tax | -95.73M | -56.80M | -94.19M | -33.94M | -1.12M | -857.94K | -1.23M | -179.90K | -92.66K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -9.54M | -1.16M | 164.00K | -3.69 | -1.91 | -1.70 | 0.00 | -0.39 |
| Net Income | -95.73M | -47.26M | -93.04M | -34.10M | -1.12M | -857.94K | -1.23M | -179.90K | -92.66K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.44 | -1.53 | -3.40 | -1.92 | -2.94 | -2.74 | -4.85 | -2.24 | -1.17 |
| EPS Diluted | -2.44 | -1.53 | -3.40 | -1.92 | -2.94 | -2.74 | -4.85 | -2.24 | -1.17 |
| Weighted Avg Shares Out | 39.16M | 30.86M | 27.38M | 17.75M | 379.41K | 312.55K | 252.82K | 80.42K | 79.00K |
| Weighted Avg Shares Out (Dil) | 39.16M | 30.86M | 27.38M | 17.75M | 379.41K | 312.55K | 252.82K | 80.42K | 79.00K |
MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
NEW YORK--(BUSINESS WIRE)---- $MNMD--Enrollment completed for MMED007, the Phase 2a study evaluating repeated low-dose administration of MM-120 for the treatment of adults with ADHD.
Mind Medicine: Q4 Of 2023 Data For GAD Makes This Worth A Look
Results from the phase 2b study, using MM-120 for the treatment of patients with generalized anxiety disorder, expected Q4 of 2023. The Generalized Anxiety Disorder market is set to reach $7.4 billion in 2023. Results from phase 2a proof-of-concept study,...
3 Pharma Stocks to Dump Before the Damage Is Done
Pharma stocks and the biotech sector can offer explosive gains. It also offers incredibly crushing defeats in which share prices decline precipitously.
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will present preclinical data for MM-402 in a model for autism spectrum disorder.
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit.
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed has completed enrollment and dosing in Study MMED008, the Phase 2b study evaluating MM-120 (lysergide D-tartrate) for the treatment of GAD.
MindMed to Participate at September Investor Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--The MindMed management team will participate in two September investor conferences.
MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed has entered into a senior secured credit facility with K2 HealthVentures, a healthcare-focused specialty finance company.
Mind Medicine Inc. (MNMD) Q2 2023 Earnings Call Transcript
Mind Medicine Inc. (NASDAQ:MNMD ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Rob Barrow - Chief Executive Officer Schond Greenway - Chief Financial Officer Dan Karlin – Chief Medical Officer Conference Call Participants Charles...
MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed today reported its financial results for the quarter ended June 30, 2023.
Source: https://incomestatements.info
Category: Stock Reports